Skip to Content

New Drug Approvals Archive - November 2012

Get news by email or subscribe to our news feeds.

November 2012

November 2

Xarelto (rivaroxaban)

New Indication Approved: November 2, 2012

Xarelto (rivaroxaban) FDA Approval History

November 6

Xeljanz (tofacitinib) Tablets

Date of Approval: November 6, 2012
Company: Pfizer Inc.
Treatment for: Rheumatoid Arthritis

Xeljanz (tofacitinib) is an oral Janus kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active rheumatoid arthritis.

Xeljanz (tofacitinib) FDA Approval History

November 19

Promacta (eltrombopag)

New Indication Approved: November 16, 2012

Promacta (eltrombopag) FDA Approval History

November 20

Flucelvax (influenza virus vaccine)

Date of Approval: November 20, 2012
Company: Novartis
Treatment for: Influenza Prophylaxis

Flucelvax (influenza virus vaccine) is an inactivated vaccine indicated for active immunization for the prevention of influenza.

Flucelvax (influenza virus vaccine) FDA Approval History

November 29

Cometriq (cabozantinib) Capsules

Date of Approval: November 29, 2012
Company: Exelixis, Inc.
Treatment for: Thyroid Cancer

Cometriq (cabozantinib) is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.

Cometriq (cabozantinib) FDA Approval History